At a glance
ClinicalIndex Comparison RecordN/ACompleted· 42 enrolled
Drug / intervention
pioglitazone +1 moredrug
Likely dose
pioglitazone 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Pioglitazone on Pancreatic Steatosis and Bone Health
University of Texas Southwestern Medical Center·interventional·Posted Mar 3, 2009·Updated Dec 13, 2017
In Brief
A clinical study evaluating pioglitazone and placebo for Obesity and Type 2 Diabetes. Completed, enrolled 42 participants across 1 site.
Detailed Summary
Randomized, double blind, placebo controlled trial evaluating the effect of pioglitazone on pancreatic fat content and bone turnover markers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Type 2 Diabetes
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedMar 2009
Primary CompletionDec 2013
TodayJul 2026
First PostedMar 3, 2009
Enrollment StartFeb 1, 2009
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 17.3 years ago
Interventions
pioglitazonedrug
pioglitazone 45 mg daily
placebodrug
one daily